SCHEMBL3449652

SCHEMBL3449652

CCOC(=O)c1cc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2nc(C(F)(F)F)cc2C)cn(CCO)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
FGFR1 P11362 2/20 0.37
P2RX3 P56373 4/20 0.35
SYK P43405 2/20 0.35
MAPT P10636 1/20 0.35
BRD4 O60885 3/20 0.35
PAK1 Q13153 1/20 0.35
RAF1 P04049 2/20 0.34
BRAF P15056 1/20 0.34
JAK2 O60674 2/20 0.34
JAK1 P23458 2/20 0.34
TYK2 P29597 2/20 0.34
JAK3 P52333 2/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
CASP1 P29466 1/20 0.33
KLK7 P49862 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448528 0.95 EGFR (0.41) EGFRERBB2FGFR1P2RX3SYK
SCHEMBL3448591 0.94 EGFR (0.38) EGFRERBB2FGFR1P2RX3SYK
SCHEMBL3448963 0.92 SYK (0.36) EGFRFGFR1SYKRAF1BRAF
SCHEMBL3448507 0.90 EGFR (0.39) EGFRERBB2FGFR1P2RX3SYK
SCHEMBL3447146 0.87 RAF1 (0.37) EGFRERBB2FGFR1SYKRAF1
SCHEMBL3448714 0.87 SYK (0.38) EGFRFGFR1SYKPAK1JAK2
SCHEMBL3449131 0.86 SYK (0.37) EGFRSYKMAPTAXL
SCHEMBL3451838 0.86 EGFR (0.38) EGFRERBB2FGFR1P2RX3SYK
SCHEMBL3447261 0.86 EGFR (0.36) EGFRERBB2FGFR1SYKRAF1
SCHEMBL3451841 0.86 EGFR (0.40) EGFRERBB2FGFR1P2RX3SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD EGFR 2771/4885ERBB2 2537/4885FGFR1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.